3billion Inc
394800
Company Profile
Business description
3billion Inc specializes in artificial intelligence-driven genetic testing and drug discovery for rare diseases. The company utilizes AI-based genome interpretation technology to provide rapid and accurate diagnostics for patients world-wide. By leveraging a proprietary database of accumulated genomic data, it is strategically expanding into the drug discovery space to identify novel therapeutic targets and accelerate the development of treatments for underserved rare disease populations. Its products include 3B-GENOME, 3B-EXOME, 3B-VARIANT, 3B-INTERPRETER, and GEBRA.
Contact
415 Teheran-ro
8th floor, L7 Hotels Gangnam Tower
Gangnam-gu
Samseong-dong
Seoul
KORT: +82 7048551010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
94
Stocks News & Analysis
stocks
Investors overly concerned about AI impact on ASX share
Shares screen as undervalued after prolonged decline.
stocks
After earnings, is Palantir stock a buy, a sell, or fairly valued?
With higher-than-expected revenue expectations and a raised fair value estimate, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,139.90 | 34.50 | -0.38% |
| CAC 40 | 8,340.13 | 16.85 | 0.20% |
| DAX 40 | 24,983.42 | 31.45 | -0.13% |
| Dow JONES (US) | 50,334.00 | 198.13 | 0.40% |
| FTSE 100 | 10,361.22 | 25.01 | -0.24% |
| HKSE | 27,183.15 | 155.99 | 0.58% |
| NASDAQ | 23,246.43 | 7.76 | 0.03% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,513.68 | 67.31 | 0.50% |
| S&P 500 | 6,972.48 | 7.66 | 0.11% |
| S&P/ASX 200 | 8,867.40 | 44.20 | -0.50% |
| SSE Composite Index | 4,128.37 | 5.28 | 0.13% |